Advanced characterization of sodium alginate raft strength for the treatment of gastroesophageal reflux disease

December 21, 2020
DuPont

Webcast

*** Available On Demand *** The aim of this presentation is to highlight the effect of various formulation components on the raft properties. ***On demand available after final airing until Dec. 21, 2021***

Register Free: https://www.pharmtech.com/pt_w/alginate

Event Overview:

Gastroesophageal reflux disease (GERD) is a digestive disorder that develops from continuous exposure of the esophagus to acidic reflux from the stomach. Raft-forming anti-reflux preparation is one line of treatment wherein a viscous gel forms a physical barrier above the stomach contents and prevents it from refluxing back into the esophagus. Sodium alginate is one of the key ingredients in such formulations.

The aim of this presentation is to highlight the effect of various formulation components on the raft properties. Additionally, a novel method for raft testing will be introduced, which will help to provide a deeper understanding about the resistance of the gels against applied forces under in-vitro conditions. We will then correlate this raft strength data and the testing to understand the behavior in in-vivo conditions in the human stomach.

Key Learning Objectives:

  • Comparison of different alginate sources according to raft performance
  • Characterization of the rheo-mechanical properties of the sodium alginate raft for overall strength and recoverability of raft under applied shear forces
  • Introduction of a novel method to characterize raft resistance against applied shear force

Speakers: Rathnakar Palarapu, Analytical Team Leader, Pharma Solutions, DuPont Nutrition & Biosciences

Dr. Matthias Knarr, Research Scientist, Pharma Solutions, DuPont Nutrition & Biosciences

Time and Date: Available On Demand

On Demand Until Dec. 2021

Sponsor: DuPont

Register Free: https://www.pharmtech.com/pt_w/alginate